Stock listing
KRX:196170 Alteogen Inc. (알테오젠) 주가
Follow Alteogen Inc. into a list and get an email when it puts out news.
Share price · KRX:196170
₩174,400 KRW +3,500 (+2.0%)
Close on Nov 20, 2026
- Day range
- ₩171,500 – ₩181,700 KRWNov 20, 2026
- Volume
- 606,458 sharesNov 20, 2026
- Market cap
- ₩12.12T KRWAt the close on Nov 20, 2026 · price × 69.51M shares outstanding
- 52-week range
- ₩152,500 – ₩424,616 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩116.0B KRWMedian day 335,825 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:196170 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩174,400 | +3,500 | +2.0% | ₩172,800 | ₩181,700 | ₩171,500 | 606,458 | |
| ₩170,900 | -2,100 | -1.2% | ₩173,100 | ₩177,000 | ₩168,700 | 272,904 | |
| ₩173,000 | +1,300 | +0.8% | ₩169,700 | ₩177,100 | ₩168,100 | 252,866 | |
| ₩171,700 | -4,500 | -2.6% | ₩178,000 | ₩180,700 | ₩171,100 | 218,880 | |
| ₩176,200 | -1,200 | -0.7% | ₩177,500 | ₩187,900 | ₩175,500 | 442,277 | |
| ₩177,400 | -6,100 | -3.3% | ₩181,400 | ₩184,700 | ₩174,400 | 421,301 | |
| ₩183,500 | +7,200 | +4.1% | ₩175,000 | ₩186,500 | ₩173,400 | 517,975 | |
| ₩176,300 | +7,900 | +4.7% | ₩173,400 | ₩181,900 | ₩172,500 | 651,815 | |
| ₩168,400 | -32,100 | -16.0% | ₩196,000 | ₩198,300 | ₩152,500 | 2,714,874 | |
| ₩200,500 | -11,000 | -5.2% | ₩194,400 | ₩204,000 | ₩193,600 | 427,896 | |
| ₩211,500 | +7,500 | +3.7% | ₩213,500 | ₩224,000 | ₩209,500 | 507,164 | |
| ₩204,000 | -9,500 | -4.4% | ₩213,500 | ₩213,500 | ₩193,100 | 729,315 | |
| ₩213,500 | +500 | +0.2% | ₩209,500 | ₩220,500 | ₩209,500 | 278,651 | |
| ₩213,000 | +1,500 | +0.7% | ₩206,500 | ₩216,500 | ₩206,500 | 183,151 | |
| ₩211,500 | -8,500 | -3.9% | ₩222,500 | ₩223,000 | ₩208,500 | 320,978 | |
| ₩220,000 | -3,000 | -1.3% | ₩225,000 | ₩226,500 | ₩216,500 | 225,094 | |
| ₩223,000 | +4,500 | +2.1% | ₩219,500 | ₩228,500 | ₩219,000 | 230,809 | |
| ₩218,500 | 0 | 0.0% | ₩220,500 | ₩229,500 | ₩217,000 | 224,003 | |
| ₩218,500 | -6,000 | -2.7% | ₩217,000 | ₩224,500 | ₩216,500 | 155,196 | |
| ₩224,500 | -6,500 | -2.8% | ₩227,500 | ₩229,000 | ₩220,500 | 229,076 | |
| ₩231,000 | -9,000 | -3.8% | ₩238,500 | ₩239,000 | ₩229,000 | 168,685 | |
| ₩240,000 | +9,000 | +3.9% | ₩236,000 | ₩243,500 | ₩235,000 | 248,776 | |
| ₩231,000 | -8,000 | -3.3% | ₩233,500 | ₩238,000 | ₩226,000 | 205,001 | |
| ₩239,000 | +5,000 | +2.1% | ₩232,000 | ₩239,000 | ₩229,000 | 264,953 | |
| ₩234,000 | +20,500 | +9.6% | ₩214,500 | ₩240,500 | ₩214,500 | 546,934 | |
| ₩213,500 | -11,000 | -4.9% | ₩214,000 | ₩218,000 | ₩209,000 | 392,922 | |
| ₩224,500 | 0 | 0.0% | ₩223,500 | ₩229,500 | ₩222,000 | 260,527 | |
| ₩224,500 | -7,000 | -3.0% | ₩220,000 | ₩228,000 | ₩217,500 | 397,458 | |
| ₩231,500 | -9,500 | -3.9% | ₩238,000 | ₩241,000 | ₩230,000 | 346,024 | |
| ₩241,000 | -16,000 | -6.2% | ₩239,000 | ₩246,000 | ₩234,500 | 724,009 | |
| ₩257,000 | -3,000 | -1.2% | ₩265,000 | ₩265,500 | ₩256,500 | 235,563 | |
| ₩260,000 | +500 | +0.2% | ₩259,000 | ₩266,500 | ₩256,500 | 281,458 | |
| ₩259,500 | -5,500 | -2.1% | ₩263,500 | ₩268,000 | ₩257,000 | 234,723 | |
| ₩265,000 | +10,500 | +4.1% | ₩253,500 | ₩266,000 | ₩251,500 | 413,327 | |
| ₩254,500 | +1,000 | +0.4% | ₩253,500 | ₩259,500 | ₩252,500 | 229,571 | |
| ₩253,500 | +1,000 | +0.4% | ₩250,000 | ₩255,000 | ₩244,000 | 297,353 | |
| ₩252,500 | +2,500 | +1.0% | ₩256,500 | ₩260,000 | ₩251,500 | 270,647 | |
| ₩250,000 | +500 | +0.2% | ₩250,000 | ₩257,500 | ₩248,500 | 222,524 | |
| ₩249,500 | -5,500 | -2.2% | ₩257,000 | ₩257,500 | ₩248,500 | 276,847 | |
| ₩255,000 | +1,500 | +0.6% | ₩255,500 | ₩260,000 | ₩253,500 | 193,075 | |
| ₩253,500 | -500 | -0.2% | ₩256,000 | ₩258,000 | ₩252,500 | 216,543 | |
| ₩254,000 | -1,500 | -0.6% | ₩258,500 | ₩260,000 | ₩252,000 | 205,493 | |
| ₩255,500 | -4,500 | -1.7% | ₩258,000 | ₩260,000 | ₩250,500 | 325,625 | |
| ₩260,000 | 0 | 0.0% | ₩262,000 | ₩267,500 | ₩258,500 | 266,955 | |
| ₩260,000 | -8,000 | -3.0% | ₩262,000 | ₩263,000 | ₩258,000 | 403,038 | |
| ₩268,000 | -9,000 | -3.2% | ₩268,000 | ₩271,500 | ₩265,000 | 442,647 | |
| ₩277,000 | -2,500 | -0.9% | ₩274,500 | ₩279,000 | ₩268,000 | 655,737 | |
| ₩279,500 | +2,500 | +0.9% | ₩270,000 | ₩280,500 | ₩268,500 | 544,699 | |
| ₩277,000 | -9,000 | -3.1% | ₩287,500 | ₩287,500 | ₩277,000 | 657,576 | |
| ₩286,000 | -2,500 | -0.9% | ₩288,500 | ₩290,500 | ₩283,250 | 481,793 | |
| ₩288,500 | +5,500 | +1.9% | ₩290,500 | ₩294,000 | ₩284,250 | 613,855 | |
| ₩283,000 | -15,500 | -5.2% | ₩307,000 | ₩313,500 | ₩282,000 | 1,248,714 | |
| ₩298,500 | -2,500 | -0.8% | ₩293,000 | ₩329,000 | ₩291,000 | 2,219,578 | |
| ₩301,000 | -6,500 | -2.1% | ₩303,500 | ₩306,000 | ₩297,500 | 281,391 | |
| ₩307,500 | -12,500 | -3.9% | ₩311,000 | ₩311,000 | ₩293,000 | 656,406 | |
| ₩320,000 | +8,500 | +2.7% | ₩308,500 | ₩324,500 | ₩305,000 | 615,333 | |
| ₩311,500 | 0 | 0.0% | ₩306,000 | ₩317,500 | ₩303,500 | 368,961 | |
| ₩311,500 | +6,000 | +2.0% | ₩305,000 | ₩320,000 | ₩296,500 | 770,565 | |
| ₩305,500 | -15,000 | -4.7% | ₩310,500 | ₩313,500 | ₩298,500 | 318,030 | |
| ₩320,500 | +500 | +0.2% | ₩319,000 | ₩324,500 | ₩314,000 | 376,465 | |
| ₩320,000 | -19,500 | -5.7% | ₩325,000 | ₩328,000 | ₩310,000 | 491,494 | |
| ₩339,500 | +36,000 | +11.9% | ₩333,000 | ₩344,000 | ₩322,000 | 1,019,594 |
Splits
5 splits since 2017 · KRX:196170 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 13-for-10 | Split | |
| 6-for-5 | Split | |
| 3-for-2 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- KRX:196170
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Sep 2, 2026
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Latest deck · Apr 9, 2026
Investor Presentation (April 2026)
Investor deck · 16 slides
Latest news
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Sep 2, 2026
Closed ₩283,000 (-5.2%) on Sep 3, 2026
Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
Aug 5, 2026
Closed ₩293,500 (+6.0%) on Aug 6, 2026
Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
Jun 10, 2026
Closed ₩266,923 (+10.2%) on Jun 11, 2026
Alteogen Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 5 in all · newest Sep 2, 2026 · oldest 2025
- Decks
- 3 decks · latest Apr 9, 2026
Valuation
P/E 63.2× against a median of 40.6×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩11.68T KRW
- P/E
- 63.2×
- EV/sales
- 46.0×
- EV/EBITDA
- 91.9×
- Price/book
- 22.6×
- Gross margin
- 80.9%
- Operating margin
- 47.2%
- Net margin
- 75.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alteogen Inc. · KRX:196170 | US$9.06B | US$8.73B | 63.2× | 46.0× | 91.9× | 22.6× | 75.5% | 0.0× | n/a |
| Halozyme Therapeutics, Inc. · NASDAQ:HALO | US$10.41B | US$12.59B | 21.5× | 7.0× | 18.2× | n/a | 26.9% | n/a | 0.63 |
| Kymera Therapeutics, Inc. · NASDAQ:KYMR | US$9.84B | US$8.87B | n/a | 86.8× | n/a | 6.1× | −341.8% | 0.0× | 0.92 |
| TG Therapeutics, Inc. · NASDAQ:TGTX | US$9.70B | US$9.94B | 91.4× | 11.1× | 51.5× | 16.9× | 11.8% | 1.3× | 0.70 |
| Krystal Biotech, Inc. · NASDAQ:KRYS | US$9.15B | US$8.24B | 40.6× | 17.5× | 35.3× | 6.4× | 47.9% | 0.0× | 0.69 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H · HKEX:6990 | US$8.99B | US$8.28B | 473× | 25.1× | 338× | 11.2× | 5.8% | 0.0× | n/a |
| Spyre Therapeutics, Inc. · NASDAQ:SYRE | US$8.88B | US$7.80B | n/a | 86.3× | n/a | 8.4× | −291.6% | 0.0× | 1.71 |
| Vaxcyte, Inc. · NASDAQ:PCVX | US$8.77B | US$7.70B | n/a | n/a | n/a | 3.5× | n/a | 0.1× | 1.24 |
| Praxis Precision Medicines, Inc. · NASDAQ:PRAX | US$8.40B | US$7.65B | n/a | n/a | n/a | 6.7× | n/a | 0.0× | 1.45 |
| Summit Therapeutics Inc. · NASDAQ:SMMT | US$7.96B | US$7.33B | n/a | n/a | n/a | 14.1× | n/a | 0.0× | 1.91 |
| Protagonist Therapeutics, Inc. · NASDAQ:PTGX | US$7.92B | US$7.13B | 23.1× | 12.9× | 22.0× | 7.3× | 62.0% | 0.0× | 0.93 |
| Median of the others | US$8.93B | US$8.02B | 40.6× | 17.5× | 35.3× | 7.3× | 11.8% | 0.0× | 0.93 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 358333.34 KRW · Analysts' mean
- EPS, year to Dec 2026
- 3979.44 · 6 analysts
- Revenue, year to Dec 2026
- 450.9B · 6 analysts
Team and board
| Officer | Role |
|---|---|
| Junseok Jang | Director, Investor Relations and Corporate Communications |
| Vivek Shenoy | Chief Business Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 16, 2026 · Before open | −2.5% |
| Q2 2026 | Aug 14, 2026 | −6.1% |
| Q1 2026 | May 11, 2026 · Before open | −4.5% |
| Q4 2025 | Mar 23, 2026 · Before open | −6.5% |
| Q3 2025 | Nov 13, 2025 · After close | +0.9% |
| Q2 2025 | Aug 12, 2025 · Before open | +1.1% |
| Q1 2025 | May 13, 2025 · Before open | +3.6% |
| Q3 2024 | Nov 12, 2024 · After close | −4.1% |
| Q2 2024 | Aug 14, 2024 · After close | +2.9% |
| Q1 2024 | May 16, 2024 · After close | +6.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 11, 2024 · After close | +7.5% |
| Q3 2023 | Nov 14, 2023 · After close | +10.4% |
| Q2 2023 | Aug 11, 2023 · After close | −2.5% |
| Q1 2023 | May 15, 2023 · After close | −2.2% |
| Q4 2022 | Mar 13, 2023 · Before open | 0.0% |
| Q3 2022 | Nov 11, 2022 · Before open | +4.5% |
| Q2 2022 | Aug 12, 2022 · Before open | −2.7% |
| Q1 2022 | May 16, 2022 · Before open | +0.6% |
| Q3 2021 | Nov 15, 2021 · Before open | −0.4% |
| Quarter to Jun 30, 2021 | Aug 17, 2021 · Before open | −4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 16 slides | Apr 9, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 18 slides | Jan 15, 2026 |
| Korea Investment Week 2025 | Conference | 27 slides | Sep 17, 2025 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215.9B | 102.9B | 96.5B | 28.8B | 41.1B | 42.4B | 29.2B | 13.7B | 12.1B | 6.84B |
| Cost of revenue | 50.2B | 38.8B | 65.3B | 24.3B | 33.0B | 23.7B | 18.1B | 11.7B | 11.1B | 6.21B |
| Gross profit | 165.6B | 64.1B | 31.2B | 4.53B | 8.17B | 18.8B | 11.1B | 1.96B | 1.03B | 629.4M |
| Research and development | 37.0B | 24.6B | 25.3B | 18.7B | 7.44B | 7.69B | 5.96B | 4.65B | 3.98B | |
| Selling, general and administrative | 5.55B | 13.3B | 14.9B | 14.6B | 13.0B | 10.6B | 6.63B | 3.54B | 2.46B | 2.00B |
| Operating income | 106.9B | 22.9B | -8.35B | -18.3B | -1.01B | 136.1M | -2.25B | -7.65B | -7.71B | -5.41B |
| Depreciation and amortization | 5.49B | 2.66B | 3.33B | 2.65B | 2.15B | 1.87B | 971.6M | 553.3M | 423.1M | 330.9M |
| EBITDA | 112.4B | 25.5B | -5.01B | -15.6B | 1.14B | 2.00B | -1.28B | -7.10B | -7.29B | -5.08B |
| Interest expense | 11.0B | 674.9M | 670.9M | 425.5M | 604.7M | 796.8M | 0 | 0 | 0 | 0 |
| Income before tax | 162.7B | 36.6B | -3.56B | -9.97B | 1.58B | -2.84B | -1.68B | -6.03B | -7.37B | -4.46B |
| Income tax | 108.0M | 893.2M | 583.1M | 57.6M | 1.04B | 76.7M | -869.0M | |||
| Net income | 141.7B | 62.3B | -3.37B | -8.15B | 6.00B | -969.6M | -704.5M | -6.87B | -7.45B | -3.59B |
| Earnings per share, basic | 2,648.85 | 1,168.07 | -65.16 | -158.19 | 141.85 | -23.02 | -16.90 | -181.19 | -196.90 | -96.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 66.4B | 19.0B | 30.2B | 45.8B | 10.5B | 38.9B | 4.41B | 8.92B | 5.23B | 8.39B |
| Short-term investments | 363.6B | 166.3B | 80.4B | 81.7B | 191.5B | 94.7B | 57.6B | 42.6B | 27.2B | 28.9B |
| Receivables | 4.81B | 17.2B | 14.3B | 7.31B | 2.08B | 1.56B | 1.84B | 4.63B | 1.45B | 1.65B |
| Inventory | 6.53B | 956.9M | 1.07B | 1.57B | 1.05B | 459.7M | 881.6M | 475.8M | 216.1M | 195.1M |
| Current assets | 480.8B | 211.8B | 144.1B | 139.3B | 210.2B | 137.9B | 65.2B | 58.3B | 35.7B | 39.3B |
| Property, plant and equipment | 19.6B | 19.3B | 27.2B | 29.6B | 19.5B | 19.2B | 11.7B | 5.03B | 4.73B | |
| Goodwill | 113.0M | 113.0M | 113.0M | 113.0M | 113.0M | 113.0M | 113.0M | 113.0M | 113.0M | |
| Total assets | 698.7B | 409.0B | 256.1B | 245.5B | 260.3B | 159.2B | 86.0B | 71.4B | 43.0B | 47.9B |
| Accounts payable | 11.2B | 10.0B | 1.01B | 159.5M | 1.41B | 440.2M | 1.03B | 1.62B | 1.30B | 1.51B |
| Current liabilities | 239.7B | 129.2B | 100.4B | 13.1B | 11.9B | 11.1B | 9.76B | 2.48B | 2.70B | 2.22B |
| Long-term debt | 4.03B | 5.00B | 1.25B | 687.5M | 937.5M | 687.5M | 1.00B | 1.50B | ||
| Total debt | 3.57B | 4.15B | 1.80B | |||||||
| Total liabilities | 244.3B | 134.9B | 108.3B | 96.7B | 123.6B | 28.0B | 16.0B | 4.76B | 3.17B | 2.72B |
| Shareholders' equity | 445.2B | 273.6B | 148.1B | 148.8B | 136.7B | 131.2B | 70.0B | 66.6B | 39.8B | 45.2B |
| Shares outstanding | 53.5M | 53.3M | 51.7M | 51.5M | 42.3M | 42.1M | 41.7M | 37.9M | 37.8M | 37.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 124.1B | 53.0B | -7.77B | -17.9B | -9.46B | 1.51B | 9.13B | -9.11B | -4.35B | -3.16B |
| Capital spending | -33.4B | -24.4B | -43.4B | -6.42B | -13.6B | -5.12B | -8.16B | -7.20B | -706.5M | -2.55B |
| Free cash flow | 90.7B | 28.6B | -51.2B | -60.4B | -33.5B | -3.82B | -102.7M | -16.3B | -5.05B | -5.71B |
| Cash from investing | -107.8B | -9.34B | 50.2B | -125.9B | -42.9B | -22.0B | -22.8B | -319.1M | -5.05B | |
| Cash from financing | 43.3B | 1.74B | 2.92B | 107.0B | 76.1B | 8.63B | 35.4B | 1.67B | 9.39B | |
| Share buybacks | -1.37B | 27.1B | 2.39B | 2.56B | 2.93B | 76.4B | 6.44B | 33.6B | 1.67B | 9.48B |
| Change in cash | 47.4B | -11.2B | -15.6B | 35.3B | -28.4B | 34.5B | -4.50B | 3.69B | -3.16B | 1.31B |
Cap table
Built by 6ix from Alteogen Inc.’s releases · as of Jun 30, 2026
- Common shares
- 69,513,590
- Fully diluted
- 69,513,590
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 69,513,590 | Jun 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Jun 30, 2026 | 69,563,176 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Junseok Jang | Director, Investor Relations and Corporate Communications · Since at least Jun 10, 2026 |
| Vivek Shenoy | Chief Business Officer · Since at least Sep 2, 2026 |
Log in to ask 6ix AI your own questions about Alteogen Inc.